Production (Stage)
BioCryst Pharmaceuticals, Inc.
BCRX
$10.59
$0.201.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 56.89% | 40.83% | 34.98% | 32.54% | 34.87% |
| Total Other Revenue | -- | -- | -- | -- | 969.78% |
| Total Revenue | 56.89% | 40.83% | 34.98% | 32.54% | 34.87% |
| Cost of Revenue | -12.40% | -17.20% | -7.72% | -24.60% | -3.18% |
| Gross Profit | 130.42% | 188.98% | 87.92% | 130.99% | 131.35% |
| SG&A Expenses | 38.62% | 25.68% | 28.50% | 20.03% | 24.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.91% | 3.74% | 10.88% | -2.54% | 10.35% |
| Operating Income | 246.51% | 88.06% | 164.52% | 142.32% | 49.01% |
| Income Before Tax | 102.16% | 58.85% | 62.46% | 83.24% | 33.51% |
| Income Tax Expenses | 98.90% | 156.18% | 77.58% | -76.76% | -45.60% |
| Earnings from Continuing Operations | 100.09% | 56.59% | 61.18% | 83.17% | 33.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 100.09% | 56.59% | 61.18% | 83.17% | 33.66% |
| EBIT | 246.51% | 88.06% | 164.52% | 142.32% | 49.01% |
| EBITDA | 252.01% | 93.26% | 169.59% | 144.74% | 49.37% |
| EPS Basic | 100.12% | 57.85% | 64.43% | 84.58% | 39.31% |
| Normalized Basic EPS | 102.17% | 56.67% | 65.59% | 74.83% | 39.18% |
| EPS Diluted | 100.06% | 58.02% | 64.43% | 84.65% | 39.31% |
| Normalized Diluted EPS | 102.07% | 56.67% | 65.59% | 74.83% | 39.18% |
| Average Basic Shares Outstanding | 1.37% | 2.97% | 9.10% | 9.15% | 9.31% |
| Average Diluted Shares Outstanding | 4.46% | 2.97% | 9.10% | 9.15% | 9.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |